Navigation Links
Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
Date:6/1/2010

EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.

"Based on insights gained from our ongoing carfilzomib development program and ONX 0912's favorable preclinical profile – anti-tumor activity, safety and biodistribution – we believe ONX 0912 may have the potential to expand the use of proteasome inhibitors in the treatment of cancer," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals.  "As an orally-dosed agent, ONX 0912 is designed to provide prolonged proteasome inhibition and easy combinability with other orally available therapies."  

Trial Design

This multicenter, open-label, dose-escalation study is evaluating the safety and tolerability of ONX 0912 in up to 50 patients with advanced refractory or recurrent solid tumor malignancies for which standard curative measures do not exist or are no longer effective.  The trial will determine the maximum tolerated dose (MTD), dose limiting toxicities, and pharmacokinetics/pharmacodynamics of ONX 0912 when administered orally on days 1 through 5 of a 14-day cycle.  Cohorts of 3 to 6 patients will receive ONX 0912 at escalating doses, starting at 30 mg, until MTD is determined.  Treatment will be repeated in 14-day cycles. The trial will be conducted in the United States.

About Onyx's Proteasome Inhibitor Development Program


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
2. Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research
3. Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line
4. Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
7. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results
10. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
11. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 63rd PHARMACHINA Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
(Date:7/30/2015)... According to a new market ... PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), ... by End Users - Global Forecast to 2020", published ... USD 2,107.99 million by 2020 from USD 1,034.93 million ... Browse more than 75 ...
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Potawatomi Business Development Corp. has purchased the remaining ... OneProspect Technologies , and plans to open a OneProspect ... business division of the Potawatomi Business Development Corp., is ... In January of 2006, the corporation had purchased a ...
... filed a registration statement with the Securities and Exchange Commission ... Madison-based medical device manufacturer has filed a Form S-1 ... ,The number of shares to be offered and the price range ... statement filed with the SEC, the maximum aggregate offering will be ...
... business to continue its transformation over the next decade, as ... to a Part I of a report on ... the California-based provider of business and financial management software. , ... , paints an emerging profile of the nation's 26 million ...
Cached Biology Technology:TomoTherapy files registration statement for IPO 2Small-business trends: Intuit sees more mom-preneurs 2Small-business trends: Intuit sees more mom-preneurs 3Small-business trends: Intuit sees more mom-preneurs 4
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... pledged to participate in ELIXIR ( www.elixir-europe.org ), a ... research in Europe. With one of Europe,s larger economies ... infrastructure is well placed to continue its excellent progress. ... sustainable infrastructure for managing biological data to support research ...
... the "fuel" that drives electric cars in effect, the vehicles, ... must be avoided. A battery,s "comfort zone" lies between 20C and ... summer can push a battery,s temperature well beyond that range. The ... of 45C instead of 35C halves its service life. And batteries ...
... of Medicine have identified five rare mutations in a single gene ... an autism spectrum disorder (ASD). Mutations in the AFF2 gene, ... why autism spectrum disorders affect four times as many boys as ... out of 202) of boys examined. Mutations in X chromosome genes ...
Cached Biology News:Italy pledges to be part of ELIXIR research infrastructure 2Keeping electric vehicle batteries cool 2Mutations in autism susceptibility gene increase risk in boys 2
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... refrigerators, freezers, or liquid nitrogen. Conveniently sized to fit ... coding to project, user, lab, etc. Holes in the ... circulation. Supplied with 9 x 9 (12.7 mm cell) ... 13 x 13 x 5.1 cm H (5 1/4 ...
RABBIT ANTI PARATHION...
Biology Products: